Abingworth LLP - 28 Jan 2022 Form 4 Insider Report for Sierra Oncology, Inc.

Reporting relationship: 10%+ Owner
Issuer ticker: N/A
Reported as of: 28 Jan 2022
Net transaction value: +$7,844,617
SEC form: 4
Accepted by SEC: 01 Feb 2022, 16:00:39 UTC
Prior SEC filing: 05 Nov 2021
Next SEC filing: 23 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ John Heard, as attorney-in-fact

Key filing fact

Abingworth LLP filed Form 4 for Sierra Oncology, Inc. on 01 Feb 2022.

Key facts

This page summarizes Abingworth LLP's Form 4 filing for Sierra Oncology, Inc..
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 01 Feb 2022, 16:00.

Change

Previous filing in this sequence was filed on 05 Nov 2021.
Current net transaction value: +$7,844,617.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SRRA transaction

Common Stock, $0.001 par value

Exercise of in-the-money or at-the-money derivative security

Transaction value: $3,794,617
Shares: +287,471
Change %: +33%
Price: $13.20
Shares after: 1,164,127
Date: 28 Jan 2022
Ownership: See footnote
Footnotes: F1

SRRA transaction

Common Stock, $0.001 par value

Purchase

Transaction value: $4,050,000
Shares: +150,000
Change %: +13%
Price: $27.00
Shares after: 1,314,127
Date: 31 Jan 2022
Ownership: See footnote
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SRRA transaction Derivative

Series B Warrants (right to buy)

Exercise of in-the-money or at-the-money derivative security

Transaction value: $0
Shares: -287,471
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 28 Jan 2022
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 287,471
Exercise price: $13.20
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of ABV VII. Abingworth General Partner VII LLP, serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV VII. Abingworth LLP holds the reported securities indirectly through ABV VII. Abingworth LLP disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, ABV VII, Dr. Andrew Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Footnote F2

Each Series B warrant will expire on the 75th day anniversary of the Issuer's announcement of top-line data from its MOMENTUM Phase 3 clinical trial of momelotinib.